Clinical Trial Results

Showing: All studies [change]
Condition: Breast Cancer Location: Kansas 25 trials found
New Search
Filter
Trial Phase
Study Type
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
PHASE3INTERVENTIONAL Phoenix, Arizona +4 more
RECRUITING
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
PHASE1INTERVENTIONAL Duarte, California +4 more
RECRUITING
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
PHASE2INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
N/AOBSERVATIONAL Anchorage, Alaska +4 more
RECRUITING
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
PHASE3INTERVENTIONAL Phoenix, Arizona +4 more
RECRUITING
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
PHASE3INTERVENTIONAL Daphne, Alabama +4 more
RECRUITING
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
PHASE3INTERVENTIONAL Chandler, Arizona +4 more
RECRUITING
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
PHASE3INTERVENTIONAL Anchorage, Alaska +4 more
RECRUITING
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Integrated Cancer Repository for Cancer Research
N/AOBSERVATIONAL Greenwood Village, Colorado +4 more
RECRUITING
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
N/AOBSERVATIONAL Anchorage, Alaska +4 more
RECRUITING
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
NAINTERVENTIONAL Anchorage, Alaska +4 more
RECRUITING
Heuristic Tool To Improve Symptom Self-Management in Adolescents and Young Adults With Cancer
NAINTERVENTIONAL Kansas City, Missouri +4 more
RECRUITING
Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry
N/AOBSERVATIONAL Hays, Kansas +4 more
RECRUITING
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
PHASE3INTERVENTIONAL Scottsdale, Arizona +4 more
RECRUITING
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
PHASE1, PHASE2INTERVENTIONAL Los Angeles, California +4 more
RECRUITING
A Phase 1/1b Study of IAM1363 in HER2 Cancers
PHASE1INTERVENTIONAL La Jolla, California +4 more
RECRUITING
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
N/AOBSERVATIONAL Birmingham, Alabama +4 more
RECRUITING
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
PHASE3INTERVENTIONAL Dothan, Alabama +4 more
RECRUITING
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
PHASE3INTERVENTIONAL Duarte, California +4 more
RECRUITING
Filter Trials
Trial Phase
Study Type